We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Talecris Biotherapeutics Holdings Corp. (MM) | NASDAQ:TLCR | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 28.80 | 0 | 01:00:00 |
Company Description
Telacris Bio therapeutics Holding Corp. is a biopharmaceutical company that specializes in the development of plasma-derived protein therapies worldwide with a market cap of $3.56 billion.
Our last major update on TLCR's business came in late February when the company reported strong Q4 results that included sharp gains from last year.
Fourth-Quarter Results
Revenue for the period was up 5% from last year to $411 million. Net looked even better, spiking to $17 million from $1.4 million last year.
The strong results were driven by solid gains in Gamunex-C/Gamunex IGIV revenue, which was up 10% from last year to $21 million.
Margin expansion also helped the cause, with gross margin climbing to 41.2% from 39.2% last year.
Financial Profile
The company has also been very focused on strengthening its balance sheet, with cash and equivalents jumping $133 million to $198 million against long-term debt and capital lease obligations of $605 million.
Estimates
We saw some movement in estimates off the good quarter, with the current year up 7 cents in the last two months to $1.81 while the next-year estimate gained 8 cents in the same time to $1.93, a solid 7% growth projection.
Valuation
But in spite of the solid gains, the valuation picture still looks solid, with a forward P/E of 15.5X, a decent discount to its peer average of 17X.
6-Month Chart
On the chart, shares recently surged into a new all-time high after trending higher for most of the last six months. Look for support from the trend line on any weakness, take a look below.
Michael Vodicka is the Momentum Stock Strategist for Zacks.com. He is also the Editor in charge of the Zacks Momentum Trader Service.
TALECRIS BIOTHR (TLCR): Free Stock Analysis Report
Zacks Investment Research
1 Year Talecris Biotherapeutics Holdings Corp. (MM) Chart |
1 Month Talecris Biotherapeutics Holdings Corp. (MM) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions